(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.12%) $82.53
(0.64%) $2.04
(-0.54%) $2 345.00
(-1.10%) $27.36
(-0.01%) $961.40
(0.11%) $0.933
(0.16%) $11.00
(0.04%) $0.796
(0.01%) $93.31
Live Chart Being Loaded With Signals
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality...
Stats | |
---|---|
Šios dienos apimtis | 2 500.00 |
Vidutinė apimtis | 93 465.00 |
Rinkos kapitalizacija | 159.14B |
EPS | ¥0 ( 2024-01-30 ) |
Kita pelno data | ( ¥110.76 ) 2024-05-06 |
Last Dividend | ¥40.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 13.42 |
ATR14 | ¥3.37 (0.09%) |
Tūris Koreliacija
Kissei Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Kissei Pharmaceutical Koreliacija - Valiuta/Žaliavos
Kissei Pharmaceutical Finansinės ataskaitos
Annual | 2022 |
Pajamos: | ¥67.49B |
Bruto pelnas: | ¥32.38B (47.97 %) |
EPS: | ¥228.30 |
FY | 2022 |
Pajamos: | ¥67.49B |
Bruto pelnas: | ¥32.38B (47.97 %) |
EPS: | ¥228.30 |
FY | 2022 |
Pajamos: | ¥65.38B |
Bruto pelnas: | ¥31.24B (47.78 %) |
EPS: | ¥280.20 |
FY | 2021 |
Pajamos: | ¥69.04B |
Bruto pelnas: | ¥32.72B (47.39 %) |
EPS: | ¥113.25 |
Financial Reports:
No articles found.
Kissei Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥40.00 (N/A) |
¥0 (N/A) |
¥40.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥7.00 | 2001-03-27 |
Last Dividend | ¥40.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥794.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.68 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.36 | |
Div. Directional Score | 7.40 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8600.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8182.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7564.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
6768.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6104.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4820.T | Ex Dividend Junior | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4028.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
3245.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
2270.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
9107.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.165 | 1.500 | 6.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0534 | 1.200 | 8.22 | 9.86 | [0 - 0.3] |
returnOnEquityTTM | 0.0620 | 1.500 | -0.422 | -0.634 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.93 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.22 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.155 | 1.500 | 4.69 | 7.04 | [0.2 - 2] |
debtRatioTTM | 0.00608 | -1.500 | 9.90 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 141.28 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00707 | -1.500 | 9.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.482 | 1.000 | 5.29 | 5.29 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0345 | 1.000 | -1.310 | -1.310 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 6.04 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.323 | 0.800 | -1.182 | -0.946 | [0.5 - 2] |
Total Score | 10.43 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.21 | 1.000 | 8.77 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0620 | 2.50 | -0.272 | -0.634 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.29 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 186.97 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0896 | 1.500 | -2.74 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.114 | 1.000 | 9.65 | 0 | [0.1 - 0.5] |
Total Score | 4.36 |
Kissei Pharmaceutical
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.